Recently, Terrenoire and colleagues revealed drug actions, including sodium-channel blocker mexiletine, in a long-QT syndrome patient with complex genetics, de novo SCN5A LQT3 mutation and a polymorphism in KCNH2 (gene for LQT2) [167]. The gene discussed is KCNH2; the disease is Prolonged QT interval.